Aligos Therapeutics, Inc. (ALGS) Operating income 2019–2025
Aligos Therapeutics, Inc. (ALGS) annual operating income history from SEC filings — each fiscal year as reported.
-$88.0MFY2025 · since FY2019: -$54.0M → -$88.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$88.0M | +1.3% |
| FY2024 | -$89.2M | -1.2% |
| FY2023 | -$88.1M | +9.7% |
| FY2022 | -$97.6M | +24.0% |
| FY2021 | -$128.3M | -31.2% |
| FY2020 | -$97.8M | -81.0% |
| FY2019 | -$54.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ALGS financial trends
ALGS RevenueALGS Net incomeALGS Net marginALGS Gross profitALGS Gross marginALGS Operating marginALGS Operating cash flowALGS Free cash flowALGS Capital expendituresALGS Return on equityALGS Stock buybacksALGS Dividends paidALGS Total assetsALGS Total liabilitiesALGS Shareholders’ equityALGS overview →